Company Announcements

Form 38.5(b) - Willis Towers Watson PLC

Source: RNS
RNS Number : 7860D
Goldman Sachs & Co. LLC
30 October 2020
 

 

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

1. KEY INFORMATION

 

Name of exempt principal trader

GOLDMAN SACHS & CO. LLC

Company dealt in

WILLIS TOWERS WATSON PLC

Class of relevant security to which the dealings being disclosed relate (Note1)

USD 0.000304635 ordinary shares

Date of dealing

29 October 2020

 

2. INTERESTS AND SHORT POSITIONS

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in  (Note 2)

 

 

Long

Short

 

Number

(%)

Number

(%)

(1) Relevant securities

520,909.542

(0.40)

302,219.542

(0.23)

(2) Derivatives (other than options)

50,872

(0.03)

373,212

(0.28)

(3) Options and agreements to purchase/sell

0

(0.00)

0

(0.00)

Total

571,781.542

(0.44)

675,431.542

(0.52)

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in  (Note 2)

 

Class of relevant security:

Long

Short

 

Number

(%)

Number

(%)

(1) Relevant securities

 

 

 

 

(2) Derivatives (other than options)

 

 

 

 

(3) Options and agreements to purchase/sell

 

 

 

 

Total

 

 

 

 

 

3.    DEALINGS (Note 3)

(a) Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit  (Note 4)

Purchase

1

186.2500 USD

Purchase

95

186.2500 USD

Purchase

780

186.2500 USD

Purchase

17

186.2500 USD

Purchase

347

186.2500 USD

Purchase

3

186.2500 USD

Purchase

93

186.2500 USD

Purchase

4

186.2500 USD

Purchase

950

186.2500 USD

Purchase

1,694

186.2500 USD

Purchase

657

186.2500 USD

Purchase

100

192.6300 USD

Purchase

93

192.8200 USD

Sale

230

186.2500 USD

Sale

315

186.2500 USD

Sale

24

186.2500 USD

Sale

1,452

186.2500 USD

Sale

10

190.4200 USD

Sale

25

190.4250 USD

Sale

31

190.6400 USD

Sale

25

191.0100 USD

Sale

25

191.1100 USD

Sale

1

191.3000 USD

Sale

24

191.3400 USD

Sale

10

191.5000 USD

Sale

15

191.5000 USD

Sale

51

191.6500 USD

Sale

26

191.8500 USD

Sale

25

191.8800 USD

Sale

25

191.9200 USD

Sale

19

191.9200 USD

Sale

25

191.9400 USD

Sale

6

191.9400 USD

Sale

25

191.9400 USD

Sale

25

191.9450 USD

Sale

25

191.9600 USD

Sale

25

191.9600 USD

Sale

25

191.9900 USD

Sale

25

192.0400 USD

Sale

9

192.0700 USD

Sale

16

192.0750 USD

Sale

25

192.2550 USD

Sale

25

192.9200 USD

Sale

20

192.9200 USD

Sale

7

192.9200 USD

Sale

34

192.9200 USD

Sale

5

192.9200 USD

Sale

1

192.9200 USD

Sale

180

192.9200 USD

Sale

100

192.9300 USD

Sale

100

192.9800 USD

Sale

11

193.1400 USD

Sale

100

193.1700 USD

Sale

75

193.1900 USD

Sale

100

193.1900 USD

Sale

100

193.1900 USD

 

(b) Derivatives transactions (other than options transactions)

 

Product name, e.g. CFD

Nature of transaction  (Note 5)

Number of relevant securities  (Note 6)

Price per unit  (Note 4)

CFD

Reducing a long position

347

186.2500 USD

 

(c) Options transactions in respect of existing relevant securities

 

(i) Writing, selling, purchasing or varying

 

Product name,e.g. call option

Writing, selling,  purchasing, varying etc.

Number of securities to which the option relates  (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit  (Note 4)

 

 

 

 

 

 

 

 

(ii)            Exercising

 

Product name,e.g. call option

Number of securities

Exercise price per unit  (Note 4)

 

 

 

 

(d)            Other dealings (including transactions in respect of new securities)  (Note 3)

 

Nature of transaction  (Note 7)

Details

Price per unit (if applicable)  (Note 4)

 

 

 

 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.  If none, this should be stated. 

NONE

 

Is a Supplemental Form 8 attached? (Note 9)        YES

 

Date of disclosure

30 October 2020

Contact name

Kashif Rafiq and Papa Lette

Telephone number

+44(20) 7051 0547 / +44(20) 7774 7442

Name of offeree/offeror with which connected

WILLIS TOWERS WATSON PLC

Nature of connection (Note 9)

Advisor to Offeree

 

SUPPLEMENTAL FORM 38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DETAILS OF OPEN POSITIONS

 

OPEN POSITIONS (Note 1)

 

Product name,e.g. call option

Written or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)

Type, e.g. American, European etc.

Expiry date

Swap

Sold

185

0.0000

N/A

23/09/2021

Swap

Sold

273

0.0000

N/A

04/01/2021

Swap

Sold

43,330

0.0000

N/A

14/04/2021

Swap

Sold

69,482

0.0000

N/A

14/04/2021

 

Notes

1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

2. For all prices and other monetary amounts, the currency must be stated.

For full details of disclosure requirements, see Rules 8 and 38.5 of the Rules. If in doubt, consult the Panel.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISEWPGCWUUPUGGU